Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background Second-generation antihistamine-decongestant combinations are often used to treat seasonal allergies. However, onset of action and efficacy data for these agents in a controlled setting are limited.Objective Determine onset of action of fexofenadine-pseudoephedrine (Allegra-D, Aventis, Bridgewater, NJ) for treating moderate-to-severe seasonal allergies in an allergen exposure unit.Methods This single-dose, double-blind, placebo-controlled study was conducted during the fall ragweed allergy season. Qualifying subjects attended one to two priming visits; those with sufficient symptom scores returned for treatment and were initially exposed to ragweed pollen for 90 minutes. Symptomatic subjects received fexofenadine-pseudoephedrine or placebo and recorded symptoms for 6 hours postdose. Efficacy variables were major symptom complex (MSC; sneezes, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, stuffy nose), total symptom complex (nose blows, sniffles, postnasal drip, cough, plus all MSC symptoms), and all individual symptoms as well as headache. Onset of action for each efficacy variable was calculated as the earliest time at which a consistent, significant decrease was seen for fexofenadine-pseudoephedrine versus placebo.Results Of 571 screened subjects, 298 were randomized. Onset of relief for fexofenadine-pseudoephedrine (n = 148) was 45 minutes postdose (MSC, P = 0.0127; total symptom complex, P = 0.0380). All individual symptoms were reduced to a greater extent with fexofenadine-pseudoephedrine than with placebo (P < 0.05, not adjusted for multiple comparisons). Decrease in headache with fexofenadine-pseudoephedrine versus placebo began 45 minutes postdose (P = 0.0425). Incidence of treatment-related adverse events was 1.4% for fexofenadine-pseudoephedrine and 3.3% for placebo.Conclusions Fexofenadine-pseudoephedrine was safe and effective in treating a broad range of allergy symptoms, with a rapid onset of action at 45 minutes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the given level of technical and clinical validation, ACCs have been intensively used in clinical drug development to study pharmacological properties of new drugs during phase II trials, such as dose-finding,1039-1041 onset of action,1042-1046 and duration of action.1047-1049”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1044]
Citations
Cites
Dykewicz, M. S., Fineman, S., Skoner, D. P., Nicklas, R., Lee, R., Blessing-Moore, J., Li, J. T., Bernstein, I. L., Berger, W., Spector, S., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63155-9 · Cited by 652
Measuring health-related quality of life in rhinitis
Juniper, E. F. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)90000-2 · Cited by 221
Overview of comorbid associations of allergic rhinitis
Spector, S. L. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70126-x · Cited by 217
The effects of antihistamines on cognition and performance
Kay, G. G. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.106153 · Cited by 203
The prevalence and medical and economic impact of allergic rhinitis in the United States.
Meltzer, E. O. (1997) · PubMed · Cited by 134
Day, J. H., Briscoe, M. P., & Widlitz, M. D. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70172-1 · Cited by 113
Complications of Allergic Rhinitis
Settipane, R. A. (1999) · Allergy and Asthma Proceedings · doi:10.2500/108854199778339053 · Cited by 110
Meltzer, E. O., Weiler, J. M., & Widlitz, M. D. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70307-x · Cited by 110
Self-citationAllergic Rhinitis: Epidemiology and Natural History
Schoenwetter, W. F. (2000) · Allergy and Asthma Proceedings · doi:10.2500/108854100778248971 · Cited by 106
Cognitive, Social, and Economic Costs of Allergic Rhinitis
Blaiss, M. S. (2000) · Allergy and Asthma Proceedings · doi:10.2500/108854100778248953 · Cited by 95
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
First do no harm: Managing antihistamine impairment in patients with allergic rhinitis
Casale, T. B., Blaiss, M. S., Gelfand, E., Gilmore, T., Harvey, P. D., Hindmarch, I., Simons, F. E. R., Spangler, D. L., Szefler, S. J., Terndrup, T. E., et al. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1550 · Cited by 139
Self-citationKarakuş, S., Küçükgüzel, İ., & Küçükgüzel, Ş. G. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.10.018 · Cited by 90
Krug, N., Loedding, H., Hohlfeld, J. M., Larbig, M., Buckendahl, A., Badorrek, P., Geldmacher, H., Behnke, W., Dunkhorst, W., Windt, H., et al. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01810.x · Cited by 73
Metadata
- Authors
- Berkowitz, R. B., Woodworth, G. G., Lutz, C., Weiler, K., Weiler, J., Moss, M., & Meeves, S.
- ORCID
- Meeves, Suzanne
- Venue
- Annals of Allergy, Asthma & Immunology
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 89
- Issue
- 1
- Pages
- 38-45
- ISSN
- 1081-1206 (ISSN-L)
- OpenAlex
- W2149609246
- Cited by
- 38
- References
- 21
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Annals of Allergy Asthma & Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- fexofenadine, pseudoephedrine, allergic rhinitis, ragweed allergy, onset of action, headache, drug safety, adverse events, placebo comparison, single-dose therapy
- MeSH terms
- Adolescent, Adult, Aged, Child, Double-Blind Method, Drug Therapy, Combination, Ephedrine, Female, Rhinitis, Allergic, Seasonal, Histamine H1 Antagonists, Humans, Male, Middle Aged, Nasal Decongestants, Terfenadine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. https://app.cochat.ai/papers/10.1016/s1081-1206(10)61909-6
- The paper
- Berkowitz, R. B., Woodworth, G. G., Lutz, C., Weiler, K., Weiler, J., Moss, M., & Meeves, S. (2002). Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/s1081-1206(10)61909-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.